MarkJHamblinMD

Pulmonology • Kansas City, KS

Critical Care Medicine, Interstitial Lung Diseases, Pleural Disease, Restrictive Lung Disease

Assistant Professor, Internal Medicine, University Kansas School of Medicine

Join to view full profile

Dr. Hamblin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hamblin's full profile

Already have an account?

Office
3901 Rainbow Blvd
# Stop
Kansas City, KS 66160
Phone+1 913-588-6046

Fax+1 913-588-4098

Education & Training

Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011
Tulane UniversityResidency, Internal Medicine, 2003 - 2007
University of Missouri-Columbia School of MedicineClass of 2003

Certifications & Licensure

KS State Medical License 2011 - 2025
MO State Medical License 2021 - 2025
LA State Medical License 2004 - 2008
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Completed
Phase 2
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
Active, not recruiting
Phase 3
Roles: Contact
Platform Clinical Study for Conquering Scleroderma Start of enrollment: 2024 Apr 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

72 citations
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis.
Ayodeji Adegunsoye, Justin M. Oldham, Evans R. Fernández Pérez, Mark J. Hamblin, Nina Patel
ERJ Open Research. 2017-07-01
43 citations
Diagnosis, course and management of hypersensitivity pneumonitis.
Mark Hamblin, Helmut Prosch, Martina Vašáková
European Respiratory Review. 2022-03-31
154 citations
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial
Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden
JAMA. 2018-06-12